dexamethasone,lenalidomide,bortezomib
takeda
['mds', 'determination', 'aml,(-streamline),(-seamless),(-kamloops)', 'mmsm']
determination is out . 2 year-pfs benefit w upfront asct vs vrd-alone. pfs in high-risk pts. 3x with asct (fig. below). no os benefit overall. mds/aml 2.7% (vs none in vrd). time to personalize upfront asct based on mrd &amp; risk-status? #mmsm #asco22 
Hematologist, Cancer Doctor, & Clinical Researcher @ColumbiaCancer #MultipleMyeloma #Amyloidosis. Asst. Prof @ColumbiaMed #ClinicalTrials & Outcomes Research